DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LATANOPROST

« Back to Dashboard

Clinical Trials for Latanoprost

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00051142	A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)	Completed	Alcon Research	Phase 3	The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.
NCT00051181	A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma	Completed	Alcon Research	Phase 3	To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
NCT00140049	A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma	Completed	Pfizer	Phase 4	To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week treatment.
NCT00143208	Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.	Completed	Pfizer	Phase 4	This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment. Eligible patients may be enrolled at the baseline visit. All current ocular hypotensive therapy must be discontinued at this time. On baseline day, patients eligible for the study will receive Xalacom which is to be instilled in the morning.

Clinical Trial Conditions for Latanoprost

Condition Name

Condition Name for Latanoprost
Intervention	Trials
Ocular Hypertension	89
Glaucoma	57
Open-Angle Glaucoma	23
Primary Open Angle Glaucoma	14

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Latanoprost
Intervention	Trials
Glaucoma	117
Ocular Hypertension	104
Glaucoma, Open-Angle	82
Hypertension	81

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Latanoprost

Trials by Country

Trials by Country for Latanoprost
Location	Trials
United States	334
Canada	13
Italy	13
Greece	12
Japan	10

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Latanoprost
Location	Trials
California	34
Texas	24
Georgia	22
New York	19
Florida	18

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Latanoprost

Clinical Trial Phase

Clinical Trial Phase for Latanoprost
Clinical Trial Phase	Trials
Phase 4	56
Phase 3	27
Phase 2/Phase 3	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Latanoprost
Clinical Trial Phase	Trials
Completed	104
Unknown status	15
Recruiting	15

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Latanoprost

Sponsor Name

Sponsor Name for Latanoprost
Sponsor	Trials
Pfizer	22
Alcon Research	13
Allergan	12

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Latanoprost
Sponsor	Trials
Industry	108
Other	66
U.S. Fed	1

Export unavailable in trial.
Subscribe for complete access.